OnBioVC is always excited to report on new funds. Provident Healthcare Ventures (Boston, MA) launched a $25M fund that is focused on investing in technologies associated with home-based healthcarecare, specialty pharma, hospice, infusion therapy and disease management. The fund will incubate early-stage start-ups and participate in more mature entities with investments ranging from 250K to $3M.


  • Greyrock Capital Group Alaven Pharmaceutical (Marietta, GA) Meda, AB (Sweeden) for $350M – representing ~6X return to investors.
  • Nycomed (Switzerland) acquired a majority stake in Guangdong Techpool Bio-Pharma (China) for $210M – representing ~51% of the company.
  • Boston Scientific (Natick, MA) acquired Sadra Medical (Los Gatos, CA) for $193M in cash plus up to an additional $193M in milestone payments.
  • Axcan Holdings (Birmingham, AL) acquired Eurand Pharma (Netherlands) for $583M ($12/shr) – representing an ~9% premium at closing.
  • Permira (United Kingdom) acquired Creganna-Tactx Medical (Ireland) for $304.7M.
  • McKesson (San Francisco, CA) is acquiring US Oncology (The Woodlands, TX) for $2.16B.


Zealand Pharma (Denmark) raised $79M via an initial public offering of 9 million shares on the Bourse in Copenhagen.


The authors of OnBioVC have launched a new web destination. For those of you interested in brushing up old or learning new business skills, for example dissecting financials or architecting out a term sheet for a financing, in your inbox, at your own pace, then run, don’t walk to The Email MBA. Better understand complicated business essentials taught at the top business schools and covered by media outlets like CNBC and Wall St. Journal. The Email MBA presents material in a clear and concise manner, using real-world (and brief…though thorough) examples. The Email MBA…Smarter, Faster.

Find some sample posts [HERE] and [HERE].